Vaspin:连接臀股部脂肪与2型糖尿病风险的新型生物标志物
研究基于PURE生物标志物亚组(N=10,052)和ORIGIN试验(N=7,840),采用回归模型和两样本孟德尔随机化分析,发现循环vaspin水平每增加1个标准差与2型糖尿病风险升高相关,且遗传决定的臀股部脂肪减少与vaspin水平升高相关,提示vaspin可能是2型糖尿病的临床预测指标。
要点
- PURE队列中vaspin每升高1-SD,新发2型糖尿病风险HR 1.16(95%CI 1.09-1.23)。
- ORIGIN队列中vaspin每升高1-SD,现患2型糖尿病OR 1.16(95%CI 1.07-1.25)。
- 遗传决定的臀股部脂肪每降低1-SD,vaspin升高0.10 SD(95%CI 0.02-0.18)。
核心结论
- 研究结果表明,较高的vaspin水平与2型糖尿病风险增加及臀股部脂肪减少相关,使vaspin成为有前景的2型糖尿病临床预测指标。
研究设计与样本
- 研究纳入PURE生物标志物亚组(N=10,052)和ORIGIN试验(N=7,840),采用回归模型分析血浆vaspin浓度与2型糖尿病及肥胖相关变量的关系,并使用两样本孟德尔随机化评估因果关系。
主要发现
- PURE队列中,循环vaspin水平每增加1-SD与新发2型糖尿病风险增加16%相关(HR 1.16;95%CI 1.09-1.23;P=4.26×10⁻⁷);ORIGIN队列中,vaspin每增加1-SD与现患2型糖尿病风险增加16%相关(OR 1.16;95%CI 1.07-1.25;P=2.17×10⁻⁴)。
- PURE组中,BMI每增加1个单位与vaspin升高0.08-SD相关(95%CI 0.06-0.10;P=2.04×10⁻¹⁵),甘油三酯每增加1个单位与vaspin升高0.06-SD相关(95%CI 0.04-0.08;P=4.08×10⁻¹³);ORIGIN队列观察到一致的关联。
- 孟德尔随机化结果强化了vaspin与BMI校正后2型糖尿病风险的关联(vaspin每增加1-SD,OR 1.01;95%CI 1.00-1.02;P=2.86×10⁻²),并显示遗传决定的臀股部脂肪每降低1-SD,vaspin升高0.10 SD(95%CI 0.02-0.18;P=2.01×10⁻²)。
- 未发现皮下脂肪或内脏脂肪与vaspin之间的关系。
临床怎么用
- 作者认为,vaspin是有前景的2型糖尿病临床预测指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether adiposity depots modulate vaspin levels and whether vaspin predicts type 2 diabetes (T2D) risk, through epidemiological and genetic analyses. RESEARCH DESIGN AND METHODS: We assessed the relationship of plasma vaspin concentration with incident and prevalent T2D and adiposity-related variables in 1) the Prospective Urban and Rural Epidemiology (PURE) biomarker substudy (N = 10,052) and 2) the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial (N = 7,840), using regression models. We then assessed whether vaspin is causally associated with T2D and whether genetic variants associated with MRI-measured adiposity depots modulate vaspin levels, using two-sample Mendelian randomization (MR). RESULTS: A 1-SD increase in circulating vaspin levels was associated with a 16% increase in incident T2D in the PURE cohort (hazard ratio 1.16; 95% CI 1.09-1.23; P = 4.26 × 10-7) and prevalent T2D in the ORIGIN cohort (odds ratio [OR] 1.16; 95% CI 1.07-1.25; P = 2.17 × 10-4). A 1-unit increase in BMI and triglyceride levels was associated with a 0.08-SD (95% CI 0.06-0.10; P = 2.04 × 10-15) and 0.06-SD (95% CI 0.04-0.08; P = 4.08 × 10-13) increase, respectively, in vaspin in the PURE group. Consistent associations were observed in the ORIGIN cohort. MR results reinforced the association between vaspin and BMI-adjusted T2D risk (OR 1.01 per 1-SD increase in vaspin level; 95% CI 1.00-1.02; P = 2.86 × 10-2) and showed that vaspin was increased by 0.10 SD per 1-SD decrease in genetically determined gluteofemoral adiposity (95% CI 0.02-0.18; P = 2.01 × 10-2). No relationships were found between subcutaneous or visceral adiposity and vaspin. CONCLUSIONS: These findings support that higher vaspin levels are related to increased T2D risk and reduced gluteofemoral adiposity, positioning vaspin as a promising clinical predictor for T2D.
引用
- Wang HH, Chong M, Perrot N, et al. Vaspin: A Novel Biomarker Linking Gluteofemoral Body Fat and Type 2 Diabetes Risk. Diabetes Care. 2024. PMID: 38055934. doi:10.2337/dc23-1488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。